FDA Approves Gazyva/Gazyvaro for Lupus Nephritis

Published on Fierce Biotech

Roche’s obinutuzumab regimen has gained FDA approval for adults with active lupus nephritis, offering a faster infusion option and improving complete renal responses compared to standard therapy in Phase III.

👉 Read the full article: Gazyva/Gazyvaro FDA approval for lupus nephritis

Disclaimer

Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full detail, refer to the original article via the provided link. SSCTR does not provide medical advice, and the views expressed are for educational purposes only.